NOREPINEPHRINE BITARTRATE INJECTION DIN 02540630
Status: Marketed
Holder: JUNO PHARMACEUTICALS CORP.
Health Canada record
| Active ingredient(s) | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | C01CA03 NOREPINEPHRINE |
| Original market date | 30-Apr-2024 |
| Current status date | 30-Apr-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Juno Pharmaceuticals Corp. (now Juno Pharma Canada Inc.) — licence 3-002647, not currently licensed, last inspection rating C (2025-01-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02501430 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION | BAXTER CORPORATION | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 0.016 MG | Marketed |
| 02501449 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION | BAXTER CORPORATION | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 0.032 MG | Marketed |
| 02538857 | NOREPINEPHRINE BITARTRATE INJECTION | AS KALCEKS | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Approved |
| 00893285 | NOREPINEPHRINE BITARTRATE INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Marketed |
| 02358743 | NOREPINEPHRINE BITARTRATE INJECTION, USP | STERIMAX INC | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Marketed |
| 02241981 | LEVOPHED | PFIZER CANADA ULC | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Cancelled Post Market |
| 02017679 | LEVOPHED LIQ IV 1.0MG/ML | SANOFI CANADA, INC. | Liquid | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Cancelled Post Market |
| 02485680 | NOREPINEPHRINE BITARTRATE INJECTION USP | GENERIC MEDICAL PARTNERS INC | Solution | NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 1 MG | Dormant |